心肌梗死患者应用瑞替普酶联合氯吡格雷治疗的疗效观察

Observation of the Curative Effect of Applying the Combination of Gatifloxacin and Clopidogrel in the Treatment of Patients with Myocardial Infarction

目的探讨心肌梗死患者应用瑞替普酶联合氯吡格雷治疗的临床效果以及应用价值。方法选取本院自2016年2月至2018年3月收治的心肌梗死患者100例,随机分为对照组和观察组,对照组患者采用常规的瑞替普酶静脉溶栓治疗方法,观察组使用在对照组的基础上增加氯吡格雷治疗方法,根据两组患者的治疗效果进行分析对比。结果使用瑞替普酶联合氯吡格雷治疗的观察组的溶栓再通率高于使用常规瑞替普酶静脉溶栓治疗的对照组,同时观察组的溶栓后再梗死概率,梗死后心绞痛概率以及心源性死亡率明显低于对照组,两组数据比较差异具有统计学意义(P<0.05)。结论使用瑞替普酶联合氯吡格雷治疗心肌梗死患者能够改善患者预后,降低不良反应率,应用价值非常高。

Objective to explore the clinical effect and value of reteplase combined with clopidogrel in patients with myocardial infarction. Methods 100 patients with myocardial infarction admitted to our hospital from February 2016 to March 2018 were selected and randomly divided into control group and observation group. The patients in the control group were treated with conventional reteptase intravenous thrombolysis. The observation group was treated with the addition of clopidogrel on the basis of the control group, and the therapeutic effects of the two groups were analyzed and compared. Results the recanalization rate of thrombolysis was higher in the observation group treated with ritipsin combined with clopidogrel than in the control group treated with conventional intravenous thrombolysis. At the same time, the probability of reinfarction after thrombolysis, the probability of angina pectoris after infarction and cardiogenic mortality were significantly lower in the observation group than in the control group, and the difference between the two groups was statistically significant （P 0.05）. Conclusion the treatment of myocardial infarction patients with reteptase combined with clopidogrel can improve the prognosis of patients and reduce the rate of adverse reactions.